The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development.
about
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitorsRecombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitorsRecombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitorsComprehensive analysis of phenotypes and genetics in 21 Chinese families with haemophilia B: characterization of five novel mutations.Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Mild hemophilia A.Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.Inhibitors in congenital coagulation disorders.Empirical and theoretical phenotypic discrimination.Thrombin generation and bleeding in haemophilia AHaemophilia A: from mutation analysis to new therapies.Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease.Optimal haemophilia care versus the reality.Characteristics of inhibitors in mild/moderate haemophilia A.Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia AKey issues in inhibitor management in patients with haemophilia.Molecular testing for disorders of hemostasis.The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment.Current options and new developments in the treatment of haemophilia.Regulation of vascular function on posttranscriptional level.Assay discrepancy in mild haemophilia A.Coagulation disorders and inhibitors of coagulation in children from Mansoura, Egypt.Genotyping of intron 22-related rearrangements of F8 by inverse-shifting PCR in Egyptian hemophilia A patients.Characterization of four novel molecular changes in the promoter region of the factor VIII gene.Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics.An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.Factor VIII genotype characterization of haemophilia A affected patients with transient and permanent inhibitors: a comprehensive Argentine study of inhibitor risks.Spectrum of Molecular Defects in 216 Chinese Families With Hemophilia A: Identification of Noninversion Mutation Hot Spots and 42 Novel Mutations.Normalization of factor VIII levels in a patient with mild haemophilia A during a 35-year period.Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development.Association of factor VIII and factor IX mutations, HLA Class II, tumour necrosis factor-α and interleukin-10 on inhibitor development among Thai haemophilia A and B patients.Heterozygous large deletions of Factor 8 gene in females identified by multiplex PCR-LC.Mutation analysis in 51 patients with haemophilia A: report of 10 novel mutations and correlations between genotype and clinical phenotype.Characterization of five associations of F8 missense mutations containing FVIII B domain mutations.Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay.Discrepant factor VIII activity in a family with mild haemophilia A and 531 mutation using various FVIII assays and APTT reagents.
P2860
Q24187069-63508DE4-4FB0-4415-9043-BBC863F115C0Q24236388-0088FC1A-F473-49C4-A5AC-F6EF7E7821E9Q24247217-5E393E1F-CB03-44A7-A5CB-2007E24DC671Q30367118-F893747B-154C-4B9A-B528-27F9AD786A97Q33715399-BE182575-33C0-4A0D-A5DD-22B44BFA5BD8Q34614695-B52FF7E1-0F14-4983-9406-3A351FBE2C2AQ35036998-36C7782A-ACB3-45BF-8BA5-A7BC458042E1Q35937076-8D0E1AFA-6B99-485B-8624-765C796CD5B5Q36090193-5402806B-1677-43B3-9D6E-59A8E9A613EBQ36090217-452C545D-59F7-4D80-A845-9ACE12495D35Q36148386-87516346-E9D4-47E6-94BD-76CF9C84F798Q36294654-4B8A8EE7-0133-4C37-81C4-955DC201C137Q36399847-C02DEB59-60EF-4E34-A12D-34B654F0CEC3Q36661826-98C77BAA-43D0-4C4A-8341-B5C06159037CQ37176534-01E901CD-FAB1-42DE-ABFE-0BBE26E4A01CQ37325682-C6F5032D-D5BC-41FC-8287-195A9492B3E4Q37377945-E0AF8102-F075-4601-B5BF-8CFAF3A97604Q37602415-94D981BD-C878-4F38-A4DE-449AA2E48DA4Q37602557-1F99131B-A0C5-4E4E-8C19-6B0D7699B30AQ37606315-C24CF125-3A54-41EC-8883-5F6C3D0F5CBCQ37818493-AC7D6ABD-748F-473E-8B87-0510BBBB7B1CQ37841547-62CAC07E-8DB9-43BD-AE78-995162715A74Q38167316-52D12C1B-E3FF-404B-8401-81AEBAF04D1BQ38222576-E07CDC16-2A61-4F13-92A3-C16AEED215D8Q38855974-86067B65-7FD8-4E79-AA85-E2CF0D9D6C29Q38857625-BC4D34E6-8443-4360-989A-03B942031E2FQ39039126-6B7E7A8E-51F8-4F17-8E00-E4E473532614Q39174749-5CDE8743-DD73-4D65-A463-8A15C35F3036Q44296354-2F4BDB10-9A24-4708-B6F5-CAD81280B375Q44858240-47A5A41E-9154-4F1B-ABFF-70F80BD8885EQ45863386-07E11108-1D3F-4BA7-B6BB-D46C1BD045F8Q45863595-7B9D135B-C59E-4949-A4B9-EDD71AC86CFBQ45864935-0C410D44-F934-492B-80F5-874DFDF5CFA2Q45867440-E387CB1A-5EF0-4D1A-96CF-AC5D7FDE43B8Q45871725-B58E9F80-A000-43B8-A548-5DDBBA0D4741Q45874698-B61FA4C2-B132-4D7B-8026-B4AA6F21383FQ45882461-A9271506-2631-459A-B62E-A40E94BB4A00Q45883537-202BDC9D-3229-4382-B8C7-4199BF16DF9AQ45885808-0164A7AD-09EC-4F65-BA9B-18F5616F102CQ45886444-980246E6-6468-4AAC-9CE6-ABA1C7E046EE
P2860
The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The molecular basis of hemophi ...... ips and inhibitor development.
@ast
The molecular basis of hemophi ...... ips and inhibitor development.
@en
type
label
The molecular basis of hemophi ...... ips and inhibitor development.
@ast
The molecular basis of hemophi ...... ips and inhibitor development.
@en
prefLabel
The molecular basis of hemophi ...... ips and inhibitor development.
@ast
The molecular basis of hemophi ...... ips and inhibitor development.
@en
P356
P1476
The molecular basis of hemophi ...... ips and inhibitor development.
@en
P2093
Ian R Peake
P356
10.1055/S-2003-37936
P577
2003-02-01T00:00:00Z